Saturday 17 October 2026
Export IRIX’s income statement to Excel — free account
IRIDEX Corporation
IRIX Healthcare Medical Devices
IRIDEX Corporation’s revenue for fiscal 2025 (year ended December 2025) was $52.7 million, up 8.23% from fiscal 2024. In the quarter to June 2026, revenue fell 7.41%, EPS fell 16.7%, free cash flow grew 130.2% and total debt rose 3.27%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.81
0.01
−1.22%
Follow IRIX
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
4 | 2 | 4 | 4 | 5 | 5 | 2 | 3 | 2 | 4 |
Altman Z-Score |
10.81 | 4.59 | 2.37 | 0.59 | 0.35 | 1.77 | (0.12) | (1.07) | (2.60) | (1.95) |
P/S ratio |
3.05 | 2.21 | 1.35 | 0.70 | 0.96 | 1.75 | 0.58 | 0.89 | 0.57 | 0.37 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.77 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
8.26 | 3.11 | 1.92 | (0.59) | (2.59) | (0.25) | (2.23) | (6.28) | (10.10) | (8.01) |
Beneish M-Score |
(3.89) | (3.78) | (2.70) | (1.04) | (3.34) | (3.13) | (2.21) | (2.81) | (3.06) | (2.75) |
P/Operating CF |
(415.62) | (98.79) | (27.95) | (161.73) | (167.04) | (54.21) | (20.65) | (47.28) | (22.31) | 32.78 |
P/B ratio |
3.60 | 3.01 | 1.91 | 1.35 | 2.00 | 4.04 | 1.91 | 4.86 | 13.17 | 0.00 |
Price to Tangible BV |
3.66 | 3.08 | 1.96 | 1.38 | 2.07 | 4.68 | 2.30 | 6.69 | 0.00 | 0.00 |
EV/Sales |
2.54 | 1.69 | 0.85 | 0.49 | 0.70 | 1.35 | 0.36 | 0.81 | 0.57 | 0.36 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(813.54) | (19.71) | (3.61) | (2.67) | (7.91) | 8.89 | (2.17) | (6.25) | (3.84) | (8.86) |
EV/FCF |
(97.14) | (16.97) | (3.45) | (2.63) | (7.69) | 9.12 | (2.11) | (6.15) | (3.83) | (8.30) |
Quick Ratio |
4.13 | 2.85 | 2.88 | 2.25 | 2.18 | 2.65 | 1.90 | 1.29 | 0.65 | 1.18 |
Current Ratio |
5.62 | 3.80 | 3.77 | 3.12 | 2.92 | 3.34 | 2.87 | 2.12 | 1.42 | 1.91 |
Net Debt/EBITDA |
13.21 | 1.81 | 1.76 | 1.14 | 1.50 | 3.15 | 1.72 | 0.79 | (0.05) | 2.68 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 9.22% | 8.93% | 5.46% | 4.18% | 0.00% | 9.40% | 12.81% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.14 | 0.14 | 0.11 | 0.10 | 0.00 | 1.31 | 0.76 |
Asset Turnover |
1.03 | 0.93 | 1.02 | 1.14 | 1.16 | 1.41 | 1.25 | 1.35 | 1.53 | 1.81 |
Operating CF/Net income |
0.01 | 0.28 | 0.78 | 0.90 | 0.51 | (1.57) | 1.26 | 0.70 | 0.82 | 0.48 |
Capex/Depreciation |
(1.38) | (0.45) | (0.54) | (0.19) | (0.18) | (0.27) | (0.59) | (0.10) | (0.01) | (0.08) |
| (32.16%) | (36.93%) | (42.37%) | (33.47%) | (31.59%) | (25.70%) | (37.24%) | (71.54%) | (153.37%) | (870.85%) | |
| (26.04%) | (28.66%) | (30.76%) | (23.05%) | (20.16%) | (13.63%) | (16.59%) | (24.95%) | (28.03%) | (15.22%) | |
ROIC |
(10.40%) | (91.38%) | (91.74%) | (42.30%) | (49.95%) | (223.88%) | (92.83%) | (251.38%) | (211.96%) | (61.12%) |
Return on Tangible Assets |
(29.86%) | (42.24%) | (42.24%) | (40.98%) | (36.95%) | (17.40%) | (31.74%) | (64.54%) | (125.18%) | (36.66%) |
Average Days of Receivables |
79.27 | 69.00 | 77.82 | 78.32 | 73.20 | 65.79 | 62.58 | 67.93 | 62.95 | 66.14 |
Research and Development Expense of Revenue |
11.62% | 12.52% | 9.40% | 8.47% | 9.03% | 12.74% | 12.59% | 13.17% | 11.20% | 6.96% |
Selling, General and Administrative Expense of Revenue |
38.82% | 56.07% | 61.81% | 53.47% | 51.89% | 43.59% | 45.17% | 48.17% | 45.93% | 34.42% |
Intangible Assets out of Total Assets |
0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.07 | 0.07 | 0.08 | 0.08 | 0.07 |
Share Based Compensation of Revenue |
3.95% | 4.62% | 4.23% | 3.92% | 3.08% | 3.02% | 2.85% | 3.18% | 2.55% | 1.47% |
Graham Net Nets |
0.26 | 0.31 | 0.49 | 0.60 | 0.42 | 0.18 | 0.33 | 0.05 | (0.13) | 0.05 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.61 |
Earnings Yield |
(8.16%) | (13.94%) | (22.55%) | (28.70%) | (17.93%) | (5.56%) | (22.82%) | (20.56%) | (32.14%) | (22.81%) |
Free Cash Flow Yield |
(0.86%) | (4.50%) | (18.25%) | (26.31%) | (9.58%) | 8.49% | (29.86%) | (14.81%) | (26.43%) | (11.70%) |
Revenue per Share |
4.54 | 3.60 | 3.49 | 3.17 | 2.63 | 3.50 | 3.57 | 3.22 | 2.96 | 3.11 |
Operating CF per Share |
(0.01) | (0.31) | (0.82) | (0.58) | (0.23) | 0.53 | (0.60) | (0.42) | (0.44) | (0.12) |
Capex per Share |
(0.10) | (0.03) | (0.04) | (0.01) | (0.01) | (0.01) | (0.02) | (0.01) | 0.00 | (0.01) |
Free Cash Flow per Share |
(0.12) | (0.34) | (0.86) | (0.59) | (0.24) | 0.52 | (0.62) | (0.42) | (0.44) | (0.13) |
Cash per Share |
2.33 | 1.88 | 1.74 | 0.92 | 0.84 | 1.55 | 0.87 | 0.44 | 0.15 | 0.36 |
Shareholders Equity per Share |
3.85 | 2.64 | 2.46 | 1.66 | 1.25 | 1.51 | 1.08 | 0.59 | 0.13 | 0.29 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.85 | 2.64 | 2.46 | 1.66 | 1.25 | 1.51 | 1.08 | 0.59 | 0.13 | 0.29 |
Free Cash Flow |
(1.21) | (3.96) | (10.46) | (8.04) | (3.33) | 8.00 | (9.80) | (6.85) | (7.30) | (2.26) |
Working Capital |
37.70 | 29.06 | 29.12 | 20.77 | 16.68 | 29.61 | 23.31 | 14.48 | 7.00 | 12.04 |
Capital Expenditures |
(1.06) | (0.40) | (0.44) | (0.13) | (0.09) | (0.21) | (0.29) | (0.11) | (0.01) | (0.14) |
Net Current Asset Value |
36.88 | 28.33 | 27.91 | 18.44 | 14.76 | 16.87 | 10.71 | 2.54 | (3.48) | 1.02 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.02 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.50 | 0.64 | 0.66 | 0.94 | 1.12 | 1.88 | 1.05 | 3.13 | 13.97 | 29.59 |
Cash ROIC |
(1.92%) | (7.59%) | (20.46%) | (20.85%) | (10.58%) | 16.07% | (29.78%) | (41.40%) | (101.05%) | (15.38%) |
Accounts Receivable Turnover |
4.78 | 4.65 | 5.03 | 4.72 | 4.38 | 6.34 | 5.85 | 5.34 | 5.39 | 5.87 |
Accounts Payable Turnover |
12.01 | 14.03 | 11.85 | 9.99 | 11.12 | 15.85 | 9.53 | 7.19 | 5.08 | 5.41 |
Inventory Turnover |
2.23 | 2.48 | 2.77 | 3.01 | 2.99 | 4.66 | 3.47 | 2.93 | 2.81 | 3.58 |
Average Days of Payables |
28.75 | 24.12 | 36.55 | 37.09 | 20.16 | 32.56 | 44.56 | 54.62 | 87.41 | 58.76 |
Days of Inventory on Hand |
167.85 | 131.24 | 127.73 | 116.96 | 100.32 | 89.44 | 122.51 | 120.27 | 135.37 | 85.96 |
Average Receivables |
9.65 | 8.94 | 8.47 | 9.20 | 8.31 | 8.50 | 9.74 | 9.71 | 9.02 | 8.97 |
Average Payables |
2.11 | 1.86 | 2.12 | 2.55 | 1.87 | 1.96 | 3.32 | 4.18 | 5.74 | 6.19 |
Average Inventory |
11.37 | 10.51 | 9.09 | 8.48 | 6.94 | 6.66 | 9.11 | 10.26 | 10.36 | 9.35 |
Average Assets |
44.98 | 44.90 | 41.66 | 38.24 | 31.39 | 38.33 | 45.49 | 38.36 | 31.79 | 29.14 |
Average Common Equity |
36.42 | 34.84 | 30.24 | 26.33 | 20.04 | 20.33 | 20.27 | 13.38 | 5.81 | 0.51 |
Columns are period end dates